KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
EBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsReceivables - NetReceivables - Other
Ratios

Nektar Therapeutics (NKTR) EBIAT (2016 - 2025)

Nektar Therapeutics has reported EBIAT over the past 16 years, most recently at -$36.1 million for Q4 2025.

  • Quarterly results put EBIAT at -$36.1 million for Q4 2025, down 596.89% from a year ago — trailing twelve months through Dec 2025 was -$164.1 million (down 37.92% YoY), and the annual figure for FY2025 was -$164.1 million, down 37.92%.
  • EBIAT for Q4 2025 was -$36.1 million at Nektar Therapeutics, down from -$35.5 million in the prior quarter.
  • Over the last five years, EBIAT for NKTR hit a ceiling of $7.3 million in Q4 2024 and a floor of -$159.1 million in Q2 2022.
  • Median EBIAT over the past 5 years was -$51.7 million (2023), compared with a mean of -$72.6 million.
  • Biggest five-year swings in EBIAT: skyrocketed 117.26% in 2024 and later crashed 596.89% in 2025.
  • Nektar Therapeutics' EBIAT stood at -$145.6 million in 2021, then soared by 59.02% to -$59.7 million in 2022, then grew by 29.5% to -$42.1 million in 2023, then surged by 117.26% to $7.3 million in 2024, then crashed by 596.89% to -$36.1 million in 2025.
  • The last three reported values for EBIAT were -$36.1 million (Q4 2025), -$35.5 million (Q3 2025), and -$41.6 million (Q2 2025) per Business Quant data.